Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus

• Status: Completed
• Trial end date: 2007-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Chronic kidney disease (CKD)has become a significant health problem worldwide. Strategies to decrease the rate of progression of this disease and reduce the number of patients needing dialysis or renal transplantation are urgently needed. In this study we wish to compare the effect of dual blockade of renin-angiotensin system (ACE inhibitors plus angiotensin II receptor blocker) compared to the effect of ACE inhibitor monotherapy in patients with diabetic chronic nephropathy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Sao Paulo
• Collaborator: Fundação de Amparo à Pesquisa do Estado de São Paulo
• Treatments: Enalapril; Enalaprilat; Losartan

Criteria

Inclusion Criteria:

• diabetic nephropathy characterised by a daily proteinuria superior to 500 mg

• type II diabetes

Exclusion Criteria:

• type 1 diabetes

• serum creatinine > 2.5 mg/dL or creatinine clearance lower than 30 ml/min

• serum potassium > 5.5 mEq/L

• intolerance or allergy to ACE inhibitors or BRA

• pregnancy

• hepatitis C or B

• HIV

• current chemotherapy treatment